PMH34 IMPROVEMENTS IN ILLNESS SEVERITY AND FUNCTIONING IN SCHIZOPHRENIC PATIENTS SWITCHED TO RISPERIDONE LONG-ACTING INJECTION (RLAI)
Peuskens J 1 , Povey M 2 , Diels J 3 ,Van der Veken J 4 , Jacobs A 3 1 Universitair Psychiatrisch Centrum, KUL Leuven, Leuven, Belgium, 2 SGS Biopharma, Wavre, Belgium, 3 Janssen Pharmaceutica, Beerse, Belgium, 4 Janssen Cilag, Berchem, Belgium OBJECTIVES: An interim analysis of changes in illness severity (Clinical Global Impression-Severity, CGI-S) and functioning (Global Assessment of Functioning, GAF) in Belgian patients with schizophrenia switched to RLAI as part of their routine management and followed up for 6 months. METHODS: e-STAR is an observational study of patients using a web-based data collection tool. Data are collected for 12 months retrospectively and 2 years prospectively for patients commencing a new antipsychotic treatment. Data reported here are for those patients who continue RLAI for 6 months. RESULTS: In Belgium 400 patients have been enrolled. Of the 206 patients with 6 months follow-up data, 86% (178 patients) have continued treatment with RLAI. Mean (SD) age of this group of patients was 40.3 (13.7) years. Mean (SD) duration of illness was 10.4 (10.3) and 62.4% were male. Most frequent reasons for a switch to RLAI were poor compliance (38.2% of patients) and need for maintenance therapy (23.5%). Mean (SD, median) CGI score at baseline was 4.5 (1.0, 5.0) (n = 142) with 16.9% patients having very mild/mild illness, 30.3% moderate, and 52.8% marked/severe/very severe. At 6 months, mean (SD, median) CGI score was significantly lower at 3.5 (1.1, 3.0) (p < 0.001) with 52.1% having mild/very mild illness (p < 0.001 versus baseline), 29.6% moderate and 18.3% marked/severe/very severe (p < 0.001). Similarly mean (SD, median) GAF score improved from 45.3 (13.6, 45.0) at baseline to 59.6 (13.7, 60.5) at 6 months (n = 142) (p < 0.001). RLAI was well tolerated; 88.8% of patients reported no adverse events (AEs). Serious AEs were reported in 8 (4.5%) patients, none of which were unequivocally related to RLAI. CONCLUSIONS: These interim data show that patients who switched to RLAI exhibit significant improvements from baseline in clinical and functional outcomes after 6 months of continual treatment. Further follow-up is ongoing. To examine whether there is a reduced incidence of suicidal ideation, violent behaviour, and deliberate self-harm in patients with schizophrenia after six months of treatment with long-acting risperidone injection (RLAI). METHODS: e-STAR is an ongoing, multinational, non-interventional, observational registry that records outcomes following a change in antipsychotic drug treatment during the management of patients with schizophrenia in a normal clinical practice setting. The incidence of suicidal ideation, violent behaviour, and deliberate self-harm (secondary objectives of the registry) were assessed at baseline and after six months of treatment with RLAI. RESULTS: Interim data are available for a total 1571 patients in Spain (n = 1005), Belgium (n = 178), and Australia (n = 388). There was a statistically significant reduction in the incidence of suicidal ideation in Spanish patients (9.4% at baseline versus 0.4% at six months, p < 0.001) and Belgian patients (6.2% versus 0.6%, p = 0.004) after six months of treatment with RLAI. Although there was a reduction in suicidal ideation in Australian patients (6.4% versus 5.2%), this was not statistically significant. There was a statistically significant reduction in violent behaviour in Spanish patients (11.1% versus 0.3%, p < 0.001), Belgian patients (11.2% versus 0.6%, p < 0.001), and Australian patients (9.0% versus 4.9%, p < 0.02) after six months. In Spain, there was a decreased incidence of deliberate self-harm after six months of treatment (3% versus 0%) and this was also seen in Belgian patients (1.7% to 0%). In Australia, the incidence of deliberate self-harm was unchanged at 2.8%. CONCLUSIONS: There was a reduction in suicidal ideation and violent behaviour after six months of treatment with RLAI in Spanish, Belgian, and Australian patients with schizophrenia. 
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